Last Updated: Tuesday, March 3, 2015, 15:50
The DC Federal Court in the US has upheld the decision of the USFDA for rescinding tentative approvals given to it for generic digestive disorder drug Nexium and antiviral Valcyte.
Last Updated: Monday, March 2, 2015, 19:56
Ranbaxy Laboratories Global Head of Human Resources Udbhav Ganjoo has resigned from the company and may join multinational pharmaceutical firm Mylan.
Last Updated: Monday, February 2, 2015, 11:14
The early termination of the waiting period under the HSR Act satisfies one of the essential conditions to the closing of the Ranbaxy acquisition, it added.
Last Updated: Saturday, January 31, 2015, 13:03
After Competition Commission of India, US fair trade watchdog FTC has asked Ranbaxy to divest one generic product as a condition for clearing its USD 4 billion deal with Sun Pharma to address monopoly concerns.
Last Updated: Tuesday, December 9, 2014, 13:14
Ranbaxy Lab's stock rose 4 percent to Rs 650.7 at the BSE.
Last Updated: Monday, December 8, 2014, 18:23
The approval, which comes within days of clearance from theFIPB, for the deal that was announced in April and would create create India's largest and world's fifth biggest drug-maker.
Last Updated: Monday, December 8, 2014, 17:49
However, the approval did not come without its share of conditions as the CCI asked the two companies to divest some products as not to affect fair competition in the market.
Last Updated: Saturday, December 6, 2014, 08:43
The US Federal Trade Commission estimates that pay-for-delay deals, in which a branded drugmaker pays a generic rival to stay off the market, cost consumers $3.5 billion each year.
Last Updated: Thursday, December 4, 2014, 16:23
The European Union has banned imports from a Ranbaxy Laboratories Ltd factory unit that makes injectable antibotics after the unit failed an inspection, the latest in a series of quality-related setbacks for the Indian drugmaker.
Last Updated: Wednesday, December 3, 2014, 21:18
In fresh overseas troubles, drugmaker Ranbaxy has been barred from exporting certain antibiotics produced at its Dewas plant to Germany for non-compliance to 'good manufacturing practice' norms.
Last Updated: Monday, December 1, 2014, 15:56
The deal, which CCI has prima-facie found to be in violation of competition norms, was inked in April this year and has been awaiting clearance from the competition watchdog since then.
Last Updated: Sunday, February 2, 2014, 12:40
Besides, auto stocks will be in focus as companies from this sector will report their sales data for January.
more videos >>
